4.5 Review

Complement in stem cells and development

Journal

SEMINARS IN IMMUNOLOGY
Volume 37, Issue C, Pages 74-84

Publisher

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.smim.2018.02.009

Keywords

Complement activation; Blastocyst; Organogenesis; Progenitor cells; Placenta; Stem cells

Categories

Funding

  1. National Health and Medical Research Council of Australia [APP1105420]
  2. Wesley Medical Research Fellowship
  3. John and Wendy Thorsen's Foundation
  4. Brazil's Family Foundation

Ask authors/readers for more resources

From its discovery in the late nineteenth century, as a 'complement' to the cellular immune response, the complement system has been widely affirmed as a powerful controller of innate and adaptive immune responses. In recent decades however, new roles for complement have been discovered, with multiple complement proteins now known to function in a broad array of non-immune systems. This includes during development, where complement exerts control over stem cell populations from fertilization and implantation throughout embryogenesis and beyond post-natal development. It is involved in processes as diverse as cell localisation, tissue morphogenesis, and the growth and refinement of the brain. Such physiological actions of complement have also been described in adult stem cell populations, with roles in proliferation, differentiation, survival, and regeneration. With such a broad range of complement functions now described, it is likely that current research only describes a fraction of the full reach of complement proteins. Here, we review how complement control of physiological cell processes has been harnessed in stem cell populations throughout both development and in adult physiology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Clinical Neurology

Monocyte CD14 and HLA-DR expression increases with disease duration and severity in amyotrophic lateral sclerosis

R. B. Mcgill, F. J. Steyn, S. T. Ngo, K. A. Thorpe, S. Heggie, R. D. Henderson, P. A. Mccombe, T. M. Woodruff

Summary: This study investigated immune marker changes in ALS patients over 16 months and found that CD14 expression on monocytes increased with disease duration and decreased ALSFRS-R score. HLA-DR expression on monocytes also increased with disease severity/duration, while CD16 expression remained unchanged. Patients had reduced non-classical monocytes and an increased classical to non-classical monocyte ratio over time, indicating potential immunological changes. These findings suggest that monocytes may play a role in ALS pathology and could serve as therapeutic targets for immunomodulatory therapies in clinical trials.

AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION (2022)

Article Immunology

Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages

Xaria X. Li, Declan M. Gorman, John D. Lee, Richard J. Clark, Trent M. Woodruff

Summary: This study compared the effects of recombinant human C5a and purified plasma-derived human C5a on the signaling and functional activities of human macrophages. The results showed similar potency in cell signaling but distinct functional responses. Recombinant C5a from commercial sources induced cytokine production in macrophages in a receptor-independent manner, which was not due to endotoxin contamination. Therefore, caution should be exercised when using recombinant human C5a in functional assays.

JOURNAL OF IMMUNOLOGY (2022)

Article Instruments & Instrumentation

Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice

Weizhi Xu, Faheem Maqbool, Vinod Kumar, James R. Falconer, Cedric S. Cui, Trent M. Woodruff, Karin Borges, Andrew K. Whittaker, Maree T. Smith, Felicity Y. Han

Summary: A sustained-release formulation of ketamine, known as KSL, was developed with high loading and demonstrated prolonged release in mice after intravenous administration. The formulation showed high encapsulation efficiency and drug loading, achieving 100% release in vitro within 8 hours.

DRUG DELIVERY AND TRANSLATIONAL RESEARCH (2022)

Review Endocrinology & Metabolism

Potential mechanisms to modify impaired glucose metabolism in neurodegenerative disorders

Tanya S. McDonald, Titaya Lerskiatiphanich, Trent M. Woodruff, Pamela A. McCombe, John D. Lee

Summary: Neurodegeneration refers to the progressive loss of neurons in disorders like Alzheimer's, Huntington's, and Parkinson's disease. Energy metabolism disturbances and alterations are common features in the onset and progression of these diseases. Understanding these metabolic changes could lead to improved treatment options for neurodegenerative disorders.

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2023)

Article Biochemistry & Molecular Biology

SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein

Eduardo A. Albornoz, Alberto A. Amarilla, Naphak Modhiran, Sandra Parker, Xaria X. Li, Danushka K. Wijesundara, Julio Aguado, Adriana Pliego Zamora, Christopher L. D. McMillan, Benjamin Liang, Nias Y. G. Peng, Julian D. J. Sng, Fatema Tuj Saima, Jenny N. Fung, John D. Lee, Devina Paramitha, Rhys Parry, Michael S. Avumegah, Ariel Isaacs, Martin W. Lo, Zaray Miranda-Chacon, Daniella Bradshaw, Constanza Salinas-Rebolledo, Niwanthi W. Rajapakse, Ernst J. Wolvetang, Trent P. Munro, Alejandro Rojas-Fernandez, Paul R. Young, Katryn J. Stacey, Alexander A. Khromykh, Keith J. Chappell, Daniel Watterson, Trent M. Woodruff

Summary: COVID-19 infection may lead to neurological symptoms similar to Parkinson's disease. The study found that SARS-CoV-2 and spike protein can directly activate the NLRP3 inflammasome in microglial cells, which may contribute to the development of neuroinflammation.

MOLECULAR PSYCHIATRY (2023)

Article Immunology

TLQP-21 is a low potency partial C3aR activator on human primary macrophages

Xaria X. Li, John D. Lee, Han S. Lee, Richard J. Clark, Trent M. Woodruff

Summary: TLQP-21 is a neuropeptide derived from the VGF precursor protein and has pleiotropic roles in regulating metabolism, nociception, and microglial functions. TLQP-21 acts through several receptors, with C3aR being the most commonly reported. However, its activity in immune cells, which express C3aR, remains understudied. This study found that TLQP-21 induced ERK signaling in human and mouse macrophages, with mouse TLQP-21 being more potent than the human counterpart. These findings suggest a significant discrepancy in TLQP-21 C3aR activity between human and murine receptors in immune cells.

FRONTIERS IN IMMUNOLOGY (2023)

Article Oncology

Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy

Andrew O. Yam, Jacqueline Bailey, Francis Lin, Arnolda Jakovija, Scott E. Youlten, Claudio Counoupas, Matthias Gunzer, Tobias Bald, Trent M. Woodruff, James A. Triccas, Leonard D. Goldstein, David Gallego-Ortega, Shane T. Grey, Tatyana Chtanova

Summary: Intratumoral injection of microbial bioparticles stimulates neutrophil antitumor functions, leading to remodeling of tumor tissue, repression of tumor growth, and enhancement of checkpoint inhibitor therapy. This indicates the potential of microbial therapy in the treatment of solid cancers.

CANCER RESEARCH (2023)

Editorial Material Cell Biology

Response to Comment on Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

Eduardo A. Albornoz, Richard Gordon, Vinod Kumar, Avril A. B. Robertson, Kate Schroder, Trent M. Woodruff

SCIENCE TRANSLATIONAL MEDICINE (2023)

Article Biochemical Research Methods

Protocol for cell-based screening assay to measure ERK1/2 phosphorylation as a readout for complement receptor activation

Xaria X. Li, Trent M. Woodruff

Summary: This study presents a protocol for investigating the effects of C3aR and C5aR1 receptors in vitro using phosphorylated ERK as a readout. The protocol includes steps for isolating human monocyte-derived macrophages, culturing and preparing cell lines expressing the receptors, performing pharmacological assays, and detecting phospho-ERK1/2.

STAR PROTOCOLS (2023)

Article Cell Biology

Senolytic therapy alleviates physiological human brain aging and COVID-19 neuropathology

Julio Aguado, Alberto A. Amarilla, Atefeh Taherian Fard, Eduardo A. Albornoz, Alexander Tyshkovskiy, Marius Schwabenland, Harman K. Chaggar, Naphak Modhiran, Cecilia Gomez-Inclan, Ibrahim Javed, Alireza A. Baradar, Benjamin Liang, Lianli Peng, Malindrie Dharmaratne, Giovanni Pietrogrande, Pranesh Padmanabhan, Morgan E. Freney, Rhys Parry, Julian D. J. Sng, Ariel Isaacs, Alexander A. Khromykh, Guillermo Valenzuela Nieto, Alejandro Rojas-Fernandez, Thomas P. Davis, Marco Prinz, Bertram Bengsch, Vadim N. Gladyshev, Trent M. Woodruff, Jessica C. Mar, Daniel Watterson, Ernst J. Wolvetang

Summary: Senescent cells play a significant role in brain aging and COVID-19-induced neuropathology, and senolytic therapy shows therapeutic potential in protecting against COVID-19-induced brain aging.

NATURE AGING (2023)

Meeting Abstract Biochemistry & Molecular Biology

A pathogenic role for complement C5aR1 activation in Huntington's disease

John Lee, Jianina Marallag, Trent Woodruff

MOLECULAR IMMUNOLOGY (2022)

Meeting Abstract Biochemistry & Molecular Biology

SARS-CoV-2 causes delayed complement activation in an ex vivo whole blood model

Martin Lo, Alberto Ortiz, John Lee, Eduardo Albornoz, Alexander Khromykh, Daniel Watterson, Trent Woodruff

MOLECULAR IMMUNOLOGY (2022)

Meeting Abstract Biochemistry & Molecular Biology

Complement C5aR2 contributes to the proliferation of neural progenitor cells during murine neurogenesis

Austin Read, John Lee, Trent Woodruff

MOLECULAR IMMUNOLOGY (2022)

Meeting Abstract Biochemistry & Molecular Biology

Immunoregulatory role for complement receptors in murine breast cancer

Barbara Rolfe, Stefan Sonderegger, Crystal McGirr, Trent Woodruff

MOLECULAR IMMUNOLOGY (2022)

Article Chemistry, Medicinal

In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy

Cedric S. Cui, Vinod Kumar, Declan M. Gorman, Richard J. Clark, John D. Lee, Trent M. Woodru

Summary: C5a receptor 1 inhibitors have been studied as potential therapeutic targets for autoimmune and inflammatory diseases, with PMX53 and JPE-1375 identified as drug candidates. A robust in vivo pharmacodynamic model was developed in mice, showing that both PMX53 and JPE-1375 have similar in vivo efficacy in inhibiting C5aR1-mediated responses, but PMX53 has a longer duration of action. Pharmacokinetic analysis revealed rapid distribution and elimination of both compounds, with PMX53 having a longer half-life, allowing for the development of an accurate pharmacokinetic/pharmacodynamic model.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

No Data Available